COMP <GO>
CRL vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Charles River Laboratories International Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CRL 3
— JNJ 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: JNJ
LAST: $359.41 (-4.44%) • MKT CAP: $17.95B
options-implied-move
7.40%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
7.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRL VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRL | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.40% | 25.50% | -25.10 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 18.5x | +76.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.10% | 2.97% | +0.13 | CRL | /fcf-yield <GO> |
| Operating Margin | 0.60% | 34.70% | -34.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 28.50% | -32.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 6.00% | -6.90 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.65 | 5.59 | -1.94 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.40% | 7.20% | +0.20 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.0 | 60.4 | +7.70 | CRL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.08 | +0.07 | CRL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 23.0x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.95B | $662.49B | -$644.54B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRL REV | JNJ REV | CRL GROSS % | JNJ GROSS % | CRL FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.02B | $94.19B | 44.0% | 67.9% | $557.0M | $19.70B |
| FY 2024 | $4.05B | $88.82B | 44.0% | 69.1% | $552.3M | $19.84B |
| FY 2023 | $4.13B | $85.16B | 44.0% | 44.0% | $498.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRL // BETA 1.15
JNJ // BETA 1.08